RE-BLEED
Research type
Research Study
Full title
RE-BLEED: A digital platform for identifying bleeding patients – a feasibility study
IRAS ID
292593
Contact name
Peter Watkinson
Contact email
Sponsor organisation
University of Oxford / Clinical Trials and Research Governance
Duration of Study in the UK
0 years, 3 months, 1 days
Research summary
Bleeding affects up to 40% of all trauma patients, up to 30% of all surgery patients and is one of the commonest causes of death for women giving birth. The presentation and features of bleeding are different between patients – in some cases bleeding is very obvious to recognise, but in other cases bleeding is more “hidden”, for example in the stomach. Bleeding must be stopped promptly to prevent severe illness or death.
Many studies have shown differences in how patients who bleed are treated. There is also variation in how individual patients respond to the same treatment, with some patients doing better than others. Understanding how variation in practice and patient characteristics affect outcomes will help us design and test improvements in care.Patients in hospital have regular tests that measure levels of the different types of cells in their blood and its ability to clot. For example, a drop in red blood cells can indicate that patients have suffered bleeding. More advanced blood tests are available that can provide more detailed information on why patients are bleeding and what treatments might be most effective.
This study aims to develop a real-time, hospital-wide digital system to identify patients in hospital who have suffered from bleeding and test whether this system could be used in the future to potentially identify patients to recruit into trials of new treatments or blood tests.
REC name
South Central - Hampshire A Research Ethics Committee
REC reference
21/SC/0290
Date of REC Opinion
16 Nov 2021
REC opinion
Further Information Favourable Opinion